# Cagrilintide – 10mg/vial (Research Use Only)

Backed by the Research [Read: How Incretin and Growth-Hormone-Axis Compounds in the Literature →](https://portaltowellness.net/research/glp1-adjunct-peptide-research-guide/)

### Overview

Cagrilintide is a long-acting synthetic analogue of human amylin (islet amyloid polypeptide, IAPP) engineered for extended receptor activation via fatty acid conjugation. As a potent amylin receptor (AMY1-3) agonist, cagrilintide activates calcitonin receptor-based heterodimeric complexes in the hindbrain and hypothalamus, producing potent satiety signaling, glucagon suppression, and gastric emptying modulation. Its primary research significance lies in its combination pharmacology with semaglutide (the CagriSema combination), with published clinical research investigating additive effects through amylin and GLP-1 receptor co-stimulation.

### What It Is

Cagrilintide is a 37-amino acid amylin analogue conjugated to a C20 fatty diacid chain at a specific lysine residue for albumin binding and extended half-life. It acts as a full agonist at AMY1, AMY2, and AMY3 receptor subtypes — calcitonin receptor (CTR) heterodimers with RAMP1, RAMP2, and RAMP3 respectively. MW approximately 4,100–4,200 Da. CAS number: 2381279-07-6.

### Key Research Applications

- Amylin receptor (AMY1-3) agonism and calcitonin receptor signaling research
- Satiety and appetite regulation through hindbrain amylin pathway studies
- Glucagon suppression and postprandial glycemic control mechanism research
- Gastric emptying rate modulation and gastrointestinal motility studies
- Combination pharmacology with GLP-1 agonists (amylin + GLP-1R co-stimulation research)
- CagriSema (cagrilintide + semaglutide) dual mechanism comparative studies
- Long-acting fatty acid-conjugated peptide pharmacokinetics and albumin-binding research
- Hypothalamic energy homeostasis circuits and neuropeptide receptor cross-talk studies

### Technical Specifications

| Compound | Cagrilintide |
| --- | --- |
| Type | Long-Acting Amylin Analogue (C20 fatty diacid conjugated) |
| Mechanism | AMY1/2/3 Receptor Agonist (Calcitonin Receptor Heterodimer) |
| Molecular Weight | ~4,100–4,200 Da |
| CAS Number | 2381279-07-6 |
| Developer | Novo Nordisk |
| Purity | ≥98% (supplier specification) |
| Form | Lyophilized powder |
| Vial Size | 10mg |
| Storage | −4 °F long-term |

**FOR RESEARCH USE ONLY.** Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

### Related Research (Educational)

- [Body Recomposition with GLP-1 Peptides: What the Research Shows](https://portaltowellness.net/research/body-recomposition-glp1-research/)
- [Muscle Preservation During Caloric Restriction: Research Compound Insights](https://portaltowellness.net/research/muscle-preservation-caloric-restriction-research/)
- [Visceral Fat and Metabolic Health: What Researchers Are Studying](https://portaltowellness.net/research/visceral-fat-metabolic-health-research/)

Research Library

- [Cagrilintide Semaglutide Trial Data](https://portaltowellness.net/research/cagrilintide-semaglutide-redefine-1-trial-data/)

---

Source: https://portaltowellness.net/shop/cagrilintide/
Research use only. Terms: https://portaltowellness.net/research-use-only/